Trade Report: Today, Karyopharm Therapeutics Inc. (KPTI) Stock Rating Reaffirm by Jefferies Group

Today, Karyopharm Therapeutics Inc. (KPTI) Stock Rating Reaffirm by Jefferies Group

Karyopharm Therapeutics Inc. (NASDAQ:KPTI)‘s stock had its “buy” rating restated by equities researchers at Jefferies Group in a report released on Tuesday. They presently have a $12.00 price objective on the stock. Jefferies Group’s price objective would indicate a potential upside of 21.09% from the stock’s current price.

KPTI has been the topic of a number of other research reports. Robert W. Baird reissued a “positive” rating and issued a $16.00 price target on shares of Karyopharm Therapeutics in a research report on Tuesday, September 6th. Wedbush reissued an “outperform” rating and issued a $14.00 price target on shares of Karyopharm Therapeutics in a research report on Thursday, August 4th. Vetr raised shares of Karyopharm Therapeutics from a “hold” rating to a “strong-buy” rating and set a $11.00 price target on the stock in a research report on Tuesday, September 6th. Zacks Investment Research raised shares of Karyopharm Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, July 21st. Finally, S&P Equity Research dropped their price target on shares of Karyopharm Therapeutics from $9.06 to $7.55 in a research report on Tuesday, August 30th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $15.47.

Shares of Karyopharm Therapeutics (NASDAQ:KPTI) traded down 1.00% during mid-day trading on Tuesday, hitting $9.91. 56,629 shares of the company’s stock were exchanged. Karyopharm Therapeutics has a 52 week low of $4.83 and a 52 week high of $19.38. The company’s market capitalization is $408.72 million. The firm has a 50 day moving average price of $8.72 and a 200-day moving average price of $8.34.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings results on Monday, November 7th. The company reported ($0.69) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.81) by $0.12. On average, equities analysts anticipate that Karyopharm Therapeutics will post ($3.00) EPS for the current year.

In other Karyopharm Therapeutics news, insider Ran Frenkel sold 3,309 shares of Karyopharm Therapeutics stock in a transaction on Monday, November 14th. The shares were sold at an average price of $10.06, for a total transaction of $33,288.54. Following the sale, the insider now owns 14,691 shares in the company, valued at $147,791.46. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 14.79% of the company’s stock.

A number of large investors have recently bought and sold shares of the company. JPMorgan Chase & Co. increased its stake in Karyopharm Therapeutics by 29.0% in the first quarter. JPMorgan Chase & Co. now owns 280,206 shares of the company’s stock worth $2,500,000 after buying an additional 62,969 shares in the last quarter. Wellington Management Group LLP increased its stake in shares of Karyopharm Therapeutics by 631.9% in the first quarter. Wellington Management Group LLP now owns 1,269,485 shares of the company’s stock valued at $11,323,000 after buying an additional 1,096,029 shares in the last quarter. Bank of New York Mellon Corp increased its stake in shares of Karyopharm Therapeutics by 4.3% in the second quarter. Bank of New York Mellon Corp now owns 101,558 shares of the company’s stock valued at $682,000 after buying an additional 4,173 shares in the last quarter. Swiss National Bank increased its stake in shares of Karyopharm Therapeutics by 7.3% in the second quarter. Swiss National Bank now owns 36,850 shares of the company’s stock valued at $247,000 after buying an additional 2,500 shares in the last quarter. Finally, Nationwide Fund Advisors increased its stake in shares of Karyopharm Therapeutics by 38.3% in the second quarter. Nationwide Fund Advisors now owns 21,258 shares of the company’s stock valued at $143,000 after buying an additional 5,886 shares in the last quarter. Hedge funds and other institutional investors own 49.20% of the company’s stock.

About Karyopharm Therapeutics

Related posts

Leave a Comment